Healthcare / Medical DevicesNYSE
$295.05
-4.41 (-1.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $3.5B · quality 74.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$113.1B
P/E
34.1x
↑EV/EBITDA
19.9x
↑ROE
14.5%
↑Gross Margin
64.0%
↑Debt/Equity
0.71
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2007–2025 · 18 años de histórico normalizado
Revenue CAGR
+8.3%
FCF CAGR
+9.5%
FCF margin
17.1%
FCF / Net income
1.32x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $25.12B · net income $3.25B · FCF $4.28B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||||
| Revenue | $25.12B | $25.12B | $22.59B | $20.50B | $18.45B | $17.11B | $14.35B | $14.88B | $13.60B | $12.44B | $11.32B | $9.95B | $9.68B | $9.02B | $8.66B | $8.31B | $7.32B | $6.72B | $6.72B | $6.00B |
| Net Income | $3.25B | $3.25B | $2.99B | $3.17B | $2.36B | $1.99B | $1.60B | $2.08B | $3.55B | $1.02B | $1.65B | $1.44B | $515.0M | $1.01B | $1.30B | $1.34B | $1.27B | $1.11B | $1.15B | $1.02B |
| EBITDA | $6.31B | $6.31B | $4.95B | $5.06B | $4.11B | $3.86B | $3.30B | $3.76B | $3.50B | $3.16B | $2.93B | $2.45B | $1.83B | $1.77B | $2.23B | $2.17B | $2.16B | $1.98B | — | — |
| EPS | 8.40 | 8.40 | 7.76 | 8.25 | 6.17 | 5.21 | 4.20 | 5.48 | 9.34 | 2.68 | 4.35 | 3.78 | 1.34 | 2.63 | 3.39 | 3.45 | 3.19 | 2.77 | 2.78 | 2.44 |
| Gross Margin | 64.0% | 64.0% | 63.9% | 63.7% | 62.8% | 64.1% | 63.1% | 65.1% | 65.7% | 65.7% | 66.3% | 66.4% | 65.7% | 66.7% | 67.9% | 66.2% | 68.8% | 67.5% | 68.3% | 68.9% |
| Operating Margin | 20.1% | 20.1% | 20.7% | 19.1% | 16.9% | 15.1% | 15.5% | 18.2% | 18.7% | 18.5% | 19.2% | 18.7% | 12.9% | 13.9% | 20.1% | 20.3% | 23.9% | 23.7% | 22.6% | 21.8% |
| Net Margin | 12.9% | 12.9% | 13.2% | 15.4% | 12.8% | 11.7% | 11.1% | 14.0% | 26.1% | 8.2% | 14.5% | 14.5% | 5.3% | 11.2% | 15.0% | 16.2% | 17.4% | 16.5% | 17.1% | 17.0% |
| Balance Sheet | ||||||||||||||||||||
| Debt/Equity | 0.71 | 0.71 | 0.66 | 0.70 | 0.79 | — | — | — | 0.72 | 0.66 | 0.70 | 0.38 | 0.38 | 0.30 | 0.20 | 0.23 | 0.14 | 0.00 | — | — |
| Current Ratio | 2.11 | 2.11 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||||
| Free Cash Flow | $4.28B | $4.28B | $3.49B | $3.14B | $2.04B | $2.74B | $2.79B | $1.54B | $2.04B | $961.0M | $1.43B | $711.0M | $1.55B | $1.69B | $1.45B | $1.21B | $1.36B | $1.33B | $1.02B | $840.6M |
| Returns | ||||||||||||||||||||
| ROE | 14.5% | 14.5% | 14.5% | 17.0% | 14.2% | — | — | — | 30.3% | 10.2% | 17.2% | 16.9% | 6.0% | 11.1% | 15.1% | 17.5% | 17.7% | 16.8% | 21.2% | 18.9% |
| Valuation | ||||||||||||||||||||
| P/E | 34.11 | 34.11 | 46.59 | 35.80 | 41.53 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 19.94 | 19.94 | 30.17 | 24.36 | 26.56 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 5.09 | 5.09 | 6.76 | 6.09 | 5.89 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||||
| Revenue Growth | 11.2% | 11.2% | 10.2% | 11.1% | — | 19.2% | -3.6% | 9.4% | 9.3% | 9.9% | 13.9% | 2.8% | 7.2% | 4.2% | 4.2% | 13.5% | 8.9% | 0.1% | 12.0% | — |
| EPS Growth | 8.2% | 8.2% | -5.9% | 33.7% | — | 24.0% | -23.4% | -41.3% | 248.5% | -38.4% | 15.1% | 182.1% | -49.0% | -22.4% | -1.7% | 8.2% | 15.2% | -0.4% | 13.9% | — |
| Dividend Yield | 1.2% | 1.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
46.1%
EPS terminal req.
$26.18
Spread vs growth
-37.8%
5Y implied EPS CAGR
30.4%
EPS terminal req.
$31.68
Spread vs growth
-22.2%
10Y implied EPS CAGR
19.8%
EPS terminal req.
$51.02
Spread vs growth
-11.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-21.3%
Start / end P/E
49.1x → 35.1x
EPS bridge
7.76 → 8.40
Residual
-2.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.